With the evolution of scalability of peripheral blood protein glycosylation, research has expanded for new biomarkers.
Klaus Lindpaintner
Advertisement
Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.
Articles by Klaus Lindpaintner
Advertisement
Latest Updated Articles
- Using Novel Biomarkers to Facilitate AI-Driven Glycoproteomics
November 2nd 2022
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
France Remains One of Europe’s Leading Biotech Funding Hubs
2
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
3
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
4
Investing in Protecting Pharma Products
5